Clinical Advisory Board

Expand all CVs×Hide all CVs

Carsten Reinhardt, M.D. Ph.D.

Chairman of the Clinical Advisory Board

More about:
Carsten Reinhardt, M.D. Ph.D.

CV

Besides serving as Head of Vira-T´s Clinical Advisory Board, Dr. Carsten Reinhardt currently is Managing Director and Chief Medical Officer of Immatics Biotechnologies GmbH, a global biotechnology company focused on the development of T-cell receptor (TCR)-based treatments targeting various cancer indications. He joined Immatics Biotechnologies GmbH in October 2009 from Micromet, Inc. (Bethesda, MD), where he was Chief Medical Officer and a member of the management board and instrumental in bringing BiTE® from bench to approval.

Previously, as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland), Dr Reinhardt had global responsibility for the development of Herceptin®. Prior to his tenure at Roche, Dr Reinhardt was Head of Clinical Development at Fresenius Biotech (Munich, Germany).

Dr Reinhardt has extensive experience in translational development as well as in early and late-stage clinical trial design. Under his leadership multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe. This included the set-up and oversight of pivotal trials leading to the approval of various anti-cancer drugs including Blincyto® in acute lymphoblastic leukemia (ALL), Removab® in solid tumors as well as various sBLA/MAA for Herceptin® in additional indications such as adjuvant breast cancer and gastric cancer.

Prior to joining the pharma and biotech industry, Dr Reinhardt held various academic medical positions and worked at the University of Tuebingen and Max Planck Institute, Munich to complete his curriculum in Neurology.

Dr Reinhardt has co-authored more than 40 publications in peer-reviewed journals including Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine.

Dr Reinhardt received a Medical Degree in 1994 from the University of Munich, Germany and, in addition, completed a Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany (summa cum laude). He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel.

×Show less

Prof. Dr. Ulrich Lauer

Clinical Advisor

More about:
Prof. Dr. Ulrich Lauer

CV

Prof. Lauer studied Medicine in Erlangen (Germany) and holds an MD with a thesis focussing on experimental oncology. From 1988 to 1993, he worked as a postdoctoral research fellow at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. In 1993, he became a research group leader in Gene Therapy / Virotherapy and a Fellow at the Eberhard-Karls-University Tübingen, Germany. In 2000, he achieved his Board Certification in Internal Medicine in 2000 works as a Consultant in Internal Medicine since then. In 2006, he became an Associate Professor of the Medical Faculty Tübingen. Since 2016, Prof. Lauer works as the Deputy Director of Internal Medicine VIII, which comprises the conjoint Phase I Clinical Study Unit as well as the Department of Clinical Tumor Biology of the University Hospital Tübingen. Since 2006, Prof. Lauer is also Head of the German Oncolysis Consortium (GOC). From 2012 to 2014 Prof. Lauer carried out the first German clinical virotherapy trial employing a recom­bi­nant oncolytic virus. Since 2014, Prof. Lauer is Head of the “Virotherapy Center Tübingen (VCT)”. Furthermore, Prof. Lauer is Member of the Task Force Technology Transfer and Member of the Ethics Committee of the Medical Faculty of the Eberhard-Karls-University Tübingen and the University Hospital Tübingen. Prof. Lauer holds patents on innovative virotherapeutic vectors, e.g. being entitled “Oncolytic measles virus”, EP2605783/US9272008 B2.

×Show less

Prof. Günther Gastl

Clinical Advisor

Prof. Dr. Herbert Riechelmann

Clinical Advisor